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Abstract
Parkinson’s disease is a neurodegenerative disorder characterized by the prominent degeneration of dopaminergic (DA)
neurons among other cell types. Here we report a first chemical screen of over 5,000 compounds in zebrafish, aimed at
identifying small molecule modulators of DA neuron development or survival. We find that Neriifolin, a member of the
cardiac glycoside family of compounds, impairs survival but not differentiation of both zebrafish and mammalian DA
neurons. Cardiac glycosides are inhibitors of Na+/K+ ATPase activity and widely used for treating heart disorders. Our data
suggest that Neriifolin impairs DA neuronal survival by targeting the neuronal enriched Na+/K+ ATPase a3 subunit (ATP1A3).
Modulation of ionic homeostasis, knockdown of p53, or treatment with antioxidants protects DA neurons from Neriifolin-
induced death. These results reveal a previously unknown effect of cardiac glycosides on DA neuronal survival and suggest
that it is mediated through ATP1A3 inhibition, oxidative stress, and p53. They also elucidate potential approaches for
counteracting the neurotoxicity of this valuable class of medications.
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Introduction
Since its discovery as a prominent chemical neurotransmitter in
the vertebrate nervous system, dopamine (DA) is recognized to
have many important physiological functions including the control
of movement, cognition, affect, as well as neuroendocrine
secretion [1,2]. Among various human disorders involving the
dysregulation of DA systems, Parkinson’s disease (PD) has the best-
characterized pathology of DA neurons: the degeneration of
substantia nigral DA neurons is the major cause of this most
common movement disorder (second most common neurodegen-
erative disorder after the Alzheimer’s disease). Recent studies show
that neurodegeneration in PD appears more widespread than only
affecting substantia nigral DA neurons, which possibly underlies
some of the non-motor symptoms of the disease [3]. Since its
introduction almost 50 years ago, L-DOPA, among other DA
replacement therapies, remain the mainstream symptomatic
treatments for PD, despite observations that they exert poor
control over non-motor symptoms, and moreover, that their
prolonged use leads to debilitating side effects [4]. Thus, a better
understanding of both the genetic and environmental causes of PD
will facilitate the development of new treatments with neuropro-
tective or disease-modifying effects.
DA neurons exhibit overall conserved organization and function
across vertebrates [5]. In developing zebrafish embryos, DA
neurons are detected in the ventral forebrain (posterior tubercu-
lum and hypothalamus), dorsal forebrain (telencephalon), olfactory
bulb and retina [6,7] in patterns that closely resemble those found
in the adult zebrafish brain [8]. These neurons display adult-like
ascending and descending projections shortly after hatching
[9,10]. While DA neurons are conspicuously absent from the
ventral midbrain, the ventral forebrain DA neurons ascending to
the striatum (where ventral midbrain DA neurons in mammals
project) are likely the functional counterpart of the mammalian
midbrain DA neurons [11,12].
Zebrafish is a vertebrate model organism that is highly
amenable to chemical genetic studies [13,14]. Owing to its high
fecundity and the small size of embryos and larvae that can be fit
into 96-well plates, zebrafish is particularly suitable for high
content small molecule screening in vivo. Such screens can utilize
the transparency of zebrafish embryos and larvae to monitor
perturbation of distinct molecular markers and cell types in the
context of an entire organism. Chemicals identified from small
molecule screens are important pharmacological tools for probing
the underlying biological mechanisms of disease models and can
serve as leads for developing new therapeutics. Assays employing
wild-type, mutants, or transgenic zebrafish embryos and larvae
have led to discoveries of small molecules that regulate major
signaling pathways [15,16], cellular proliferation/differentiation
[17–19], developmental toxicity [20,21], disease remodeling
[22,23], or simple forms of behavior [24,25].
Despite the functional significance of DA neurons, no small
molecule screen for modulators of DA neuron development or
survival has been reported. In this study, we report a first in vivo
small molecule screen in zebrafish with the goal of identifying
chemical regulators of DA neuron development or survival. We
uncover a previously unknown neurotoxic effect of cardiac
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glycosides on DA neurons, and identify approaches to counteract
the neurotoxicity of this class of medications.
Results
Chemical screening identifies Neriifolin, which disrupts
the pattern of DA neurons in the ventral forebrain
In order to identify small molecule regulators of DA neuron
development or survival, we established a chemical screening
platform employing embryonic and larval zebrafish. We treated
dechorionated wild-type embryos in 96-well plates (3 embryos per
well) with chemicals for 48 hours (from 24–72 hours post
fertilization, hpf), at a final concentration of 10 mM. At 72 hpf,
embryos were fixed and stained with antibodies against tyrosine
hydroxylase (TH), the rate-limiting enzyme in dopamine synthesis
and an established marker for DA and NA neurons. The pattern
of DA neurons were then visually analyzed and compared to
vehicle control (1% DMSO) (Fig. 1A). The ventral forebrain
(VFB) DA neurons were the focus of our analysis because of their
prominence and similarity to mammalian midbrain DA neurons
that degenerate in PD.
We screened two libraries: the Microsource library (containing
1520 FDA-approved compounds) and the Celera_IFLabs library
(containing 3500 compounds that are predicted to target kinases),
totaling 5020 compounds. 19 chemicals (0.3%) were identified that
altered the pattern of VFB DA neurons following treatment. After
further analyses, 17 compounds were deemed to have a general
effect on embryonic development that in turn affected VFB DA
neurons and were not pursued, thereby leaving 2 compounds
(0.03%) that affected VFB DA neuronal patterns without grossly
affecting embryonic development. One compound from the
Celera library increased VFB DA neurons. However, due to its
unknown mechanism of action, it will not be further discussed
here. The other compound named Neriifolin (Fig. 1B) was
particularly interesting to us: while it decreased the VFB DA
neurons, TH-positive NA neurons in the sympathetic ganglia were
unaffected (Fig. 1C).
Neriifolin is a member of the cardiac glycoside family of
compounds that are widely used for treating heart disorders. To
determine whether the observed effect of Neriifolin on VFB DA
neurons is a characteristic of cardiac glycosides, we tested the
effect of another cardiac glycoside, Digitoxin (Fig. 1B). When
embryos were treated with Digitoxin at 10 mM, the number of
VFB DA neurons was also decreased (Fig. 1D), suggesting that
cardiac glycosides as a class of drugs have similar effects disrupting
the patterns of VFB DA neurons.
Neriifolin impairs the survival, not the differentiation of
VFB DA neurons
To discern whether Neriifolin impairs the specification/
differentiation or the survival of DA neurons, we treated embryos
at earlier stages, from 24 hpf to 48 hpf, with 4 different
concentrations of the drug: 1, 5, 10 and 20 mM. None of these
treatments caused any obvious defect in the pattern of VFB DA
neurons (Fig. 1E). In contrast, when embryos were treated for
longer time (from 24–72 hpf), they displayed a dose-dependent
deficit in the VFB DA neurons (Fig. 1F and 1G). This was not
simply due to prolonged drug treatment, since embryos treated
from 48–72 hpf also suffered a similar deficit of DA neurons
(Fig. 1H): TH staining was cytoplasmic in control but appeared to
fill the entire cell in Neriifolin-treated embryos, indicating the lost
integrity of the nuclear membrane. These data suggest that
Neriifolin impairs the survival rather than the specification or
differentiation of VFB DA neurons.
In addition to affecting VFB DA neurons, we noted a dose-
dependent effect of Neriifolin on embryonic morphology. At high
concentrations (10 mM or higher), Neriifolin induced heart edema,
dorsal curvature of the body axis, and opaqueness in the brain that
is suggestive of overt neuro-degeneration. These observations
suggest that other cell and organ types than VFB DA neurons can
also be affected by the drug.
Na+/K+ ATPase a3 subunit (ATP1A3) is a likely target of
Neriifolin in DA neuronal death
Cardiac glycosides inhibit the activity of Na+/K+ ATPases. In
addition, they also affect growth factor receptor signaling, MAP
kinase, IP3, calcium, and NF-kB signaling [26]. The beneficial
effect of cardiac glycosides on heart function is through binding to
and inhibiting Na+/K+ ATPases, which drive ATP-dependent
active transport of potassium (K+) ions into cells and sodium (Na+)
ions out of cells. Na+/K+ ATPases are oligomers composed of at
least two polypeptides: the a-subunit and the b-subunit. The a
subunit is the catalytic subunit and contains an evolutionarily
conserved cardiac glycoside-binding pocket. In mammals, the a-
subunit exists as 4 isoforms (a1–a4) with distinct tissue-specific
expression. Among these 4 isoforms, three (atp1a1, 2, 3) are
expressed in the nervous system with a3 being the most prominent
one [27]. In zebrafish, ten genes encoding the a subunit have been
identified, and they exhibit distinctive expression patterns [28,29].
We found that the atp1a3a gene was prominently expressed in
the ventral brain region that encompassed the VFB DA neurons
(Fig. 2A). To determine the potential involvement of atp1a3 in DA
neuronal survival, we tested whether overexpression of the gene
could rescue Neriifolin-induced DA neuronal death. Since
zebrafish atp1a3a gene is highly homologous to the human atp1a3
[30], we expressed the human atp1a3 gene under the control of the
heat shock-inducible hsp70 promoter (Fig. 2B). This version of the
human atp1a3 gene carries two mutations (Q108R and N119D) in
the cardiac glycoside-binding pocket that are known to confer
resistance to Ouabain, another member of cardiac glycoside
family, hence cannot be inhibited by cardiac glycosides including
Neriifolin but otherwise is a fully functional Na+/K+ ATPase [30].
We injected this Ouabain-resistant form of atp1a3 (hsp70-ATP1A3
OR) or the control construct (hsp-GFP) into one-cell stage wild-type
zebrafish embryos, and performed a 90-minute heat shock from
22.5 hpf to 24 hpf. The heat-shocked embryos were subsequently
treated with Neriifolin for 24 hours (from 48 hpf to 72 hpf). RT-
PCR analysis confirmed the expression of human atp1a3 in the
experimental but not the control embryos (Fig. 2C). In the
embryos injected with hsp70-ATP1A3 OR, Neriifolin-induced DA
neuronal death was largely abrogated: most of the VFB DA
neurons were healthy, whereas DA neurons in control embryos
(injected with Hsp70-GFP and heat shocked) remained defective
with signs of cell shrinkage, membrane fragmentation or
disintegration (Fig. 2D–E). This data suggest that Neriifolin
impairs VFB DA neuronal survival by interfering with Na+/K+
ATPase activity.
Modulating K+/Na+ ionic homeostasis is neuroprotective
against Neriifolin-induced DA neuronal death
To understand the contribution of K+ or Na+ to Neriifolin-
induced DA neuronal death, we modulated their concentrations in
the embryonic medium by increasing [K+] and/or decreasing
[Na+]. Treatment with Neriifolin in the presence of high K+
Chemical Genetics of Dopaminergic Neurons
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(25 mM as compared to 0 mM in control) in the medium
significantly protected against DA neuronal loss compared to the
treatment with Neriifolin alone (Fig. 3A, p=0.005). However,
Neriifolin-induced DA neuronal death was only partially rescued,
as a significant difference remained between the DMSO group
and the Neriifolin/high K+ group (Fig. 3A, p,0.001).
Interestingly, when embryos were treated with Neriifolin in the
low Na+ medium (0.5 mM as compared to 14.2 mM in control),
the phenotype caused by Neriifolin was completely rescued:
significant differences were observed between (DMSO) – (Ner-
iifolin) groups (p=0.01) and (Neriifolin) – (Neriifolin low Na+)
groups (p=0.022), but there was no difference between (Neriifolin
low-Na+) – (DMSO) groups (p=0.475) (Fig. 3B). These results
suggest that Neriifolin-induced DA neuronal death is to a larger
extent caused by the accumulation of Na+ rather than the
depletion of K+. Thus, low sodium/high potassium exerts a
neuroprotective effect.
Figure 1. Zebrafish chemical screen identifies Neriifolin, a member of cardiac glycoside family, which disrupts the pattern of DA
neurons in the ventral forebrain. (A) Schematic diagram of the chemical screening platform, through which Neriifolin was identified as a hit that
decreases ventral forebrain DA neurons. (B) Structure of two cardiac glycosides, Neriifolin and Digitoxin, both of which disrupt the pattern of VFB DA
neurons. (C) Embryos treated with 10 mM Neriifolin showed a decrease of VFB DA neurons (middle panels), whereas the Sym NA neurons were normal
(right panels). (D) Treatment with another cardiac glycoside, Digitoxin, similarly decreased VFB DA neurons but not Sym NA neurons. (E) Embryos
treated with different concentrations of Neriifolin from 24 hpf to 48 hpf showed no obvious defect in the pattern of VFB DA neurons. (F) Embryos
treated with different concentrations of Neriifolin from 24 hpf to 72 hpf displayed impaired DA neuron pattern in VFB. The dose response curve is
shown in (G). (H) Embryos treated with Neriifolin from 48–72 hpf also showed deficit in VFB DA neurons: neuronal numbers in the control vs. treated
embryo are 64 and 39 respectively. The insets show enlarged views of DA neurons, which reveal the presence of TH in the nucleus, indicating a loss of
nuclear membrane integrity. OB, olfactory bulb; VFB, ventral forebrain; sym NA, sympathetic NA neurons; AAC NA, arch-associated NA; LC, locus
coeruleus.
doi:10.1371/journal.pone.0035645.g001
Figure 2. Human atp1a3 rescues DA neurons in Neriifolin-treated embryos. (A) The expression pattern of atp1a3a in wild-type embryos at
48 hpf. (B) The schematic diagram of the plasmid constructs used for the rescue experiments in zebrafish embryos. (C) RT-PCR detection of the
expression of human atp1a3 in zebrafish embryos after injection and heat shock. (D–E) Quantification (D) and representative images (E) of VFB DA
neurons in 5 mM Neriifolin-treated embryos that express either GFP or human atp1a3. Data are the averages 6 SEM from 9 embryos in a single
experiment that was repeated twice with similar results.
doi:10.1371/journal.pone.0035645.g002
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Two small molecule antioxidants, Quercetin and Ascorbic
Acid, are neuroprotective against Neriifolin-induced DA
neuronal death
To further understand Neriifolin-induced DA neuronal death
and identify small molecule compounds that may be neuropro-
tective, we tested two natural food-derived compounds: Quer-
cetin (a flavonoid abundantly present in fruits and vegetables)
and Ascorbic Acid (Vitamin C). Both compounds have
antioxidant properties and exert a neuroprotective effect against
oxidative stress-induced neurodegeneration [31,32]. Neriifolin-
induced DA neuronal death was significantly alleviated by the
treatment with either compound: significant differences were
observed between the Neriifolin control and Neriifolin/Querce-
tin (Fig. 3C, p,0.01) or Neriifolin/Ascorbic Acid groups
(Fig. 3D, p,0.05). These results suggest that Neriifolin-induced
DA neuronal death is in large part due to aggravated oxidative
stress, which may be caused by ionic imbalance due to ATP1A3
inhibition.
Inhibition of p53 is neuroprotective against Neriifolin-
induced DA neuronal death
To gain molecular insight into Neriifolin-induced DA neuronal
death, we investigated whether this process is dependent on p53, a
tumor suppressor that integrates cellular stress signal and activates
apoptosis [33–35]. We first determined whether the Neriifolin-
induced DA neuronal death is apoptotic by performing TUNEL
labeling. This analysis showed that DA neurons indeed are
preferentially TUNEL+ upon treatment with Neriifolin (Fig. 4A–
B). However, TUNEL staining was not solely restricted to DA
neurons. Nevertheless, TH-positive sympathetic NA neurons,
which were unaffected by Neriifolin, were TUNEL2, suggesting
that not all neurons were equally affected by the drug (Fig. 4C–
D). Next, we injected a well-established morpholino antisense
oligonucleotide targeting p53 [36] (with over 150 publications in
the pubMED employing this morpholino oligonucleotide) into
one-cell stage wild-type embryos (thereof referred to as p53
morphants). Control or p53 morphants were treated with
Figure 3. Mechanisms and protective strategies for Neriifolin-induced DA neuronal death. (A) Treatment with Neriifolin in the presence
of high K+ in the medium significantly decreased DA neuronal loss compared to the treatment with Neriifolin alone. Data are the averages 6 SEM
from 6 embryos in a single experiment that was repeated twice with similar results. (B) Treatment with Neriifolin in the presence of low Na+ in the
medium significantly decreased DA neuronal loss compared to the treatment with Neriifolin alone. Data are the averages6 SEM from 8 embryos in a
single experiment that was repeated twice with similar results. (C–D) Treatment with either Quercetin (C) or Ascorbic Acid (D) significantly decreased
DA neuronal death compared to treatment with Neriifolin alone. Data are the averages 6 SEM from 8 embryos in a single experiment that was
repeated twice with similar results.
doi:10.1371/journal.pone.0035645.g003
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Figure 4. Neriifolin-induced DA neuronal death is apoptotic and requires p53. (A–D90) Low (A–D) and high (A9–D90) magnification views of
VFB DA neurons in control (A-A90) vs Neriifolin-treated embryos (B-B90), and sympathetic (Sym) NA neurons in control (C-C90) vs Neriifolin-treated
embryos (D-D90). Ventral views of 60 hpf embryos were shown. Neriifolin treatment was carried out from 24 hpf to 60 hpf. (E) Injection of the p53-MO
into embryos at one-cell stage protected DA neurons from cell death induced by Neriifolin. Data are the averages 6 SEM from 6 embryos in a single
experiment that was repeated twice with similar results.
doi:10.1371/journal.pone.0035645.g004
Chemical Genetics of Dopaminergic Neurons
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Neriifolin from 24 hpf to 72 hpf. Impairment of p53 activity
exerted a complete protection of DA neurons (Fig. 4E): while
significant difference existed between the DMSO control and
Neriifolin group (p=0.009), there was no difference between
DMSO control group and Neriifolin/p53 morphant group
(p=0.417). This result indicates that Neriifolin-induced DA
neuronal apoptosis requires p53.
Impairment of DA neuronal survival by Neriifolin is
evolutionarily conserved
To determine whether mammalian DA neurons are also
vulnerable to Neriifolin, we tested the effect of the drug on
neurons derived from mouse embryonic stem cells (mESCs). The
mESC line E14 was induced to differentiate into neurons using the
monolayer differentiation method [37] (Fig. 5A). After plating
mESC cells in N2B27 media and withdrawal of LIF on Day 7,
Nestin+ and Sox2+ neural progenitors began to emerge in the
culture (Fig. S1). On Day 11, these progenitors differentiated into
nascent neurons (positive for the pan-neuronal marker NeuN with
a subset of them TH+). On Day 15, NeuN+ and TH+ neurons with
more elaborated processes were detected in the culture, indicative
of more differentiated status. Double labeling with midbrain DA
neuronal markers and TH showed that many TH+ neurons were
DA neurons of the midbrain characteristics (Fig. S2).
We treated cells with Neriifolin either from Day 7 to 11
(containing mostly neural progenitors and some nascent neurons)
or from Day 11 to 14 (containing mostly differentiated neurons).
The quantification was carried out using the InCell 2000
automated imaging and analysis software (Fig. S3). In agreement
with the in vivo zebrafish data, only cells treated from Day 11 to 14
showed decreased TH+ neurons compared to vehicle controls
(Fig. 5B–C), suggesting that Neriifolin impairs the survival rather
than the differentiation of mammalian DA neurons. Moreover, the
decrease of TH+ neurons was highly significant (p,0.005,
compared to DMSO control) but the total number of neurons
was not significantly affected compared to DMSO control
(Fig. 5D), again suggesting an increased sensitivity of DA neurons
to Neriifolin.
Discussion
By screening for chemical modulators of DA neuron develop-
ment or survival, we have uncovered a previously unknown
vulnerability of DA neurons to cardiac glycosides and also
identified strategies that protect DA neurons against the
neurotoxicity of this class of medications. Based on our data, we
propose the following model (Fig. 6) to explain Neriifolin-induced
DA neuronal death: Inhibition of Na+/K+ ATPase activity by
cardiac glycosides causes an ionic imbalance; in particular,
increased intracellular Na+ levels aggravate oxidative stress.
Through a yet unknown mechanism, this oxidative stress activates
p53, which subsequently unleashes the apoptotic cell death
pathway. Since DA neurons are known to be highly susceptible
to oxidative stress due to intrinsic metabolic processes [38], this
may explain the increased vulnerability of DA neurons to
Neriifolin, as well as to other neurotoxic compounds such as
MPTP [39–43] and rotenone [43,44], which can selectively (in the
case of MPTP) or non-selectively (in the case of rotenone) enter
DA neurons and inhibit the activity of mitochondrial complex I of
the electron transport chain [45–47].
While our data show that the sympathetic NA neurons are
unaffected by Neriifolin in zebrafish and the overall neuronal
numbers are not significantly reduced in Neriifolin-treated mESC
cultures, it is unlikely that DA neurons are the only neuronal type
affected by Neriifolin, given the broad Na+/K+ ATPase activity
detected in the brain. Although such broad expression of Na+/K+
ATPase in neurons including DA neurons favors the notion that
DA neuronal death is due to a cell autonomous mechanism, it also
makes it difficult to rule out the non-cell autonomous contributions
to Neriifolin-induced DA neuronal death.
In humans, most cardiac glycosides are known to cross both
blood-brain barriers and placental barriers. Their adverse effects
on the central nervous system have been reported that includes
depression and psychosis but not PD [48,49]. This may be due to
the fact that DA neuron degeneration takes time to manifest and
will likely result in symptoms at a much later time point after the
offensive drug exposure. While it is not known whether drug
concentrations experienced by embryonic and larval zebrafish are
comparable to brain drug concentrations in human patients, it is
worth pointing out that a single acute exposure of zebrafish to
cardiac glycosides is sufficient to impair DA neuronal survival.
Human patients usually take these drugs for longer periods of time,
so even if they are on a lower dose, prolonged exposure to cardiac
glycosides could affect DA neuronal homeostasis. Interestingly, the
atp1a3 gene in humans has been previously associated with the
rapid-onset dystonia-parkinsonism (RDP), which is characterized
by the rapid development of dystonic spasms, dysarthria,
dysphagia, and parkinsonism [30]. However, it is presently not
known whether brain DA neurons degenerate in this particular
form of parkinsonism.
Our study has demonstrated the importance of zebrafish
chemical screening for discovering previously unknown toxicity
of therapeutic compounds as well as devising strategies to
counteract their toxicity. Further chemical genetic studies of DA
neuron development or survival, including characterizing other
leads identified from this screen, and identifying more chemicals,
not only employing wild-type, but also transgenic or pharmaco-
logical models with pre-existing DA neuron degeneration, promise
to shed new light on the etiology of PD and development of
neuroprotective therapeutics.
Materials and Methods
Ethics statement
All work followed the NIH guidelines and was approved by the
University of California San Francisco Committee on Animal
Research.
Chemical screening and libraries
To screen for small molecules that can affect the differentiation
and maintenance of DA neurons in zebrafish, wild-type embryos
(in the AB genetic background) were collected and raised in Blue
Egg Water (BEW, 0.12 g. CaSO4, 0.2 g. Instant Ocean,
30 microliters methylene blue in 1 L water) to 24 hpf. After
removal of chorions, embryos were transferred into 96-well-deep-
well polypropylene plates (Fisher, #12-566-120, n = 3 embryos
per well) containing 10 mM chemicals (in 400 ml total volume).
DMSO concentration was 1%. Embryos were treated with
chemicals for 24–72 hours at 28uC. At the end of chemical
treatment, embryos were observed under a dissecting microscope
and abnormal morphologies were recorded, including the heart
rate, cardiac edema, and overall body shape. Afterwards, embryos
were transferred to a mesh-bottom-96-PCR plate for immuno-
staining with a polyclonal TH antibody (custom-made, 1:1000),
followed by visualization of DA and NA neurons under a
fluorescent dissecting microscope (Leica).
Chemical libraries were provided by the UCSF Small Molecule
Discovery Center (SMDC). Two libraries were screened: Micro-
Chemical Genetics of Dopaminergic Neurons
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Figure 5. Neriifolin selectively impairs the survival of mammalian DA neurons derived from embryonic stem cells (ESCs). (A)
Schematic diagram of the protocol used to induce DA neuron differentiation from mouse ESCs. (B) Representative views from wells with different
treatment, showing the percentage of TH+ neurons (TH, a marker of DA neurons, in red) or all neurons (NeuN, a neuronal marker, in green) among
total cells (DAPI). Compared to DMSO control (upper panel), those cells treated with Neriifolin from Day 7 to 11 (middle panels) showed no decrease
in the percentage of TH+ neurons and all neurons; but those cells treated with Neriifolin from day 11 to 14 (lower panels) showed significant less
percentage of DA neurons. (C) Quantification of the percentage of TH+ neurons among total cells. Fold change of treatment vs DMSO control was
shown. (D) Quantification of fold change of TH+ neurons and all neurons. In both (C) and (D), data are the averages 6 SEM of triplicates from a single
experiment that was repeated 3 times with similar results.
doi:10.1371/journal.pone.0035645.g005
Chemical Genetics of Dopaminergic Neurons
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source and Celera_IFLabs. The Microsource library contains
1520 compounds and the Celera library contains 3500 com-
pounds.
Immunostaining and confocal microscopy
TH immunostaining was carried out as previously described
[50,51]. TUNEL labeling was performed according to the
manufacturer’s protocol (Roche In situ Cell Death Detection
Kit). Immunostained zebrafish embryos were mounted in glycerol
and imaged using a Leica SP2 confocal microscope as a stack of
roughly 100 optical sections taken approximately 1 mm apart in
the z-dimension. This stack of images was imported into ImageJ
software and average intensity projections were created for each
zebrafish embryo.
In situ hybridization
In situ hybridization was carried out as previously described
[50].
Plasmids, morpholinos, and microinjection
The hsp70 promoter [52] was used to drive the human ATP1A3
WT OR cDNA (a generous gift from Dr. L. Ozelius). The plasmid
DNA was micro-injected into one-cell stage wild-type embryos at a
concentration of 40 ng/ml, together with 10 ng/ml transposase
RNA to increase integration of DNA and decrease possible mosaic
expression. At 22.5 hpf, embryos with normal morphology were
heat-shocked at 37uC for 90 minutes. 24 hours after heat shock
(around 48 hpf), de-chorioned embryos were transferred into
freshly made embryo media (NaCl, 13.7 mM; KCl, 0.5 mM;
Na2HPO4, 25 mM; KH2PO4, 44 mM; CaCl2, 1.3 mM; MgSO4,
1 mM; NaHCO3, 0.41 mM; pH 7.2), with 5 mM Neriifolin
(DMSO final concentration 0.5%). Neriifolin treatment lasted
from 48 hpf to 80 hpf. The embryos were collected and
immunostained afterwards.
The sequence of this p53 morpholino is: GCGCC-
ATTGCTTTGCAAGAATTG, which targets the ATG of p53
mRNA [36]. The standard control morpholino from Gene Tools
INc. was used. Control or the p53 morpholinos were injected into
one-cell-stage embryos, which were raised in Blue Egg Water until
24 hours, then transferred into Embryo Medium in a 24-well-plate
and treated with 5 mM Neriifolin. At 72 hpf, embryos were
collected and fixed, then stained with anti-TH antibody.
Mouse ESC culture and DA neuronal differentiation
Mouse embryonic stem cell line E14Tg2a was used [53]. E14
cells were cultured in GMEM media (Sigma, G5154) supplement-
ed with glutamine, sodium pyruvate, 0.1 mM MEM non-essential
amino acids, 10% (v/v) fetal bovine serum (characterized,
Hyclone), beta-mercaptoethanol, and 500–1000 units per ml of
leukocyte inhibitory factor (Chemicon ESG1107), on gelatinized
cell culture surface without feeder cells.
To induce neuronal differentiation, the monolayer differentia-
tion protocol developed by Ying et al was used [54]. Briefly, on
Day 1, E14 cells were dissociated with Trypsin-EDTA (TE) into
single cells and plated onto gelatinized cell culture dish at a density
of 1.06104 cell/cm2 in N2B27 media. Cells were cultured in
N2B27 media for 7 days (with media changes every other day) to
differentiate ESCs to neural progenitors. On day 7, cells were
dissociated with TE and re-plated onto poly-L-ornithine-laminin
coated 96-well plates in N2B27 media. Media was changed every
2 days after re-plating. On Day 15, cells were fixed with PFA and
immunostained with antibody for analysis the differentiation of
TH neurons or all neurons. For chemical treatment, chemical was
diluted into media on Day 8 or Day 11 and treatment lasted for 4
days, with media changes every other day.
Primary antibody for immunocytochemistry included: Rabbit-
anti-TH, 1:2000 (Millipore, AB152); Mouse-anti-NeuN, 1:600
(Millipore, MAB377); Nurr1 (Santa Cruz, Sc-991), Lmx1a (a
generous gift from Dr. M. S. German, UCSF). After immuno-
staining, images were taken using the automated imaging system
InCell 2000 (GE). 20 views of images were taken for each well and
for each view, images from 3 channels were taken (TH, NeuN plus
DAPI). Image stacks were segmented and quantified using the
software InCell developer. The percentage of TH neurons and all
neurons were calculated accordingly.
Supporting Information
Figure S1 Characterization of neuronal progenitors in
Day 7 mESC culture. At this stage, most cells in culture were
neuronal progenitors, as evidenced by the expression of Sox2 (top)
and Nestin (bottom).
(TIF)
Figure S2 Many TH+ cells in the mESC culture are of
midbrain DA identity. Top panels: midbrain DA markers
Nurr1; middle panels: midbrain DA markers Lmx1a; bottome
panels: the pan neuronal marker NeuN.
(TIF)
Figure S3 Quantification using automated INCell im-
aging analysis software. Representative images showing the
segmentation method used in InCell Developer software (A). (B)
Targets from different channels were segmented separately and
the area of all targets from all the views in a well is summarized.
TH% among total cells was calculated based on the areas from
TH channel and DNA channels (Cal of TH). The fold change
upon certain treatment (e.g. Neriifolin) was calculated by
computing the ratio over the control (e.g. DMSO).
(TIF)
Figure 6. A schematic model showing the effect of cardiac
glycosides on DA neuronal death. We propose that inhibition of
Na+/K+ ATPase activity leads to increased intracellular sodium, which
triggers the production of reactive oxygen species (ROS) and activation
of p53-mediated apoptotic cell death pathway. Future biochemical
experiments are needed to further test this model.
doi:10.1371/journal.pone.0035645.g006
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